aHSCT in India: A Complete Guide for International Patients

aHSCT in India: Evidence-based success rates, costs, and top hospitals. Autologous hematopoietic stem cell transplant for MS, myeloma, lymphoma with journal references.

Table of Contents

1. Overview of aHSCT
2. Conditions Treated with aHSCT
3. What the Research Shows: Success Rates
4. Risks and Side Effects
5. Recovery and Aftercare
6. Cost of aHSCT in India
7. Top Hospitals for aHSCT
8. Frequently Asked Questions
9. How MedicHorizon Assists with Your aHSCT Journey

1. Overview of aHSCT

aHSCT—autologous hematopoietic stem cell transplantation—is a procedure where a patient’s own stem cells are collected, stored, and then reinfused after high-dose chemotherapy or radiation. The goal is to “reset” the immune system and allow healthy new cells to grow. Unlike allogeneic transplants, which use donor cells, aHSCT uses the patient’s own cells, which eliminates the risk of graft-versus-host disease (GVHD).

In this procedure, stem cells are collected from the patient’s blood, frozen, and stored. The patient then receives high-dose chemotherapy or radiation to destroy diseased cells. Finally, the stored stem cells are thawed and reinfused to rebuild the bone marrow and immune system.

Over the last decade, India has emerged as one of the most trusted destinations for aHSCT. The country offers internationally trained hematologists, JCI and NABH-accredited hospitals, and state-of-the-art stem cell processing laboratories—all at a fraction of the cost compared to Western countries.

For more research insights, visit our MedicHorizon Journal.

2. Conditions Treated with aHSCT

aHSCT is used to treat a range of hematological and autoimmune conditions. The most common indications in India include:

Multiple Myeloma

Multiple myeloma is the second most common hematological malignancy in the world. A multicentre study from India analyzed 365 patients who underwent autologous HSCT. The study found that autologous SCT remains a cornerstone in the management of multiple myeloma, particularly in resource-constrained settings. Despite advances in newer drugs, ASCT continues to be the standard of care for all eligible patients and is more cost-effective than continued treatment with newer agents. A systematic review of Indian data reaffirms the utility of ASCT in resource-constrained settings.

Multiple Sclerosis

aHSCT provides long periods of progression-free survival in multiple sclerosis (MS). A study from North India on 20 patients demonstrated the safety of ASCT in MS patients using a lymphoablative regimen. No mortality was observed, and subjective symptoms improved in all patients. EDSS scores improved in 6 out of 19 patients, with no disease progression in any patient at a median follow-up of 242 days.

New transplant centres in India are now offering autologous BMT specifically for autoimmune conditions, particularly multiple sclerosis, backed by high-dose and induction therapies, targeted treatments, immunotherapies, and advanced graft manipulation.BioSpectrum India

Lymphoma

Non-cryopreserved autologous peripheral blood stem cell transplantation for lymphoma has been found feasible in resource-limited settings, with adequate CD34+ cell collection, rapid engraftment, and acceptable early survival. A study from Kashmir, India confirmed these findings.

Solid Tumors

ASCT is the standard treatment for many high-risk solid tumors, including high-risk neuroblastoma (HR-NB) and refractory/relapsed Hodgkin’s lymphoma. A study from a tertiary care centre in India reported outcomes for the first 20 pediatric patients who underwent ASCT, demonstrating that the procedure can be safely performed even in settings without HEPA filters and positive pressure, if expertise and supportive care are available.

3. What the Research Shows: Success Rates

aHSCT has demonstrated excellent outcomes in India, with success rates comparable to global standards. Here is what the latest research tells us about what you can realistically expect.

Multiple Myeloma Outcomes

A multicentre study across five tertiary care centers analyzed 365 patients (mean age: 54 ± 10.3 years) who underwent autologous HSCT between 2010 and 2024. Key findings include:

• Day +100 post-transplant response: 77% achieved complete remission (CR) or better
• 1-year overall survival (OS): 91%
• 2-year overall survival: 85%
• 5-year overall survival: 72%
• Successful autologous SCT: 96.4% of cases
• Transplant-related mortality (TRM): 3.56%

Long-term outcomes from a comprehensive review of AHSCT in MM from the Indian subcontinent reported that despite significant resource limitations in LMICs, AHSCT is increasingly being performed in MM with encouraging long-term outcomes.

Pediatric Solid Tumor Outcomes

A study of 20 pediatric patients at a tertiary care centre in India reported:

• Overall survival: 75% at a median follow-up of 33.2 months
• Disease-free survival: 60% at a median follow-up of 28.4 months
• Overall survival for Hodgkin’s lymphoma: 85.7% at a median of 45.3 months
• Overall survival for high-risk neuroblastoma: 66.7% at a median of 34.9 months

Multiple Sclerosis Outcomes

A study from North India on 20 MS patients reported:

• No mortality observed
• Subjective symptoms improved in all patients
• No disease progression in any patient at a median follow-up of 242 days
• Relapsing-remitting MS (RRMS) patients showed the most improvement

What Affects Your Chances of Success?

Your success with aHSCT depends on several factors:

• Choosing an experienced, qualified specialist and accredited centre – this matters more than anything else
• Pre-transplant response status – better response before transplant leads to better outcomes
• CD34+ cell dose – higher stem cell doses are associated with better survival
• ISS stage – earlier stage disease has better outcomes
• Early intervention – performing the procedure before the onset of severe complications dramatically improves outcomes
• Your overall health and healing capacity
• Following post-treatment care instructions carefully

4. Risks and Side Effects

Like any medical procedure, aHSCT carries some risks. However, when performed by experienced specialists in accredited hospitals, the risks are manageable.

Common Side Effects

During the first few weeks after transplant, most patients experience side effects that typically resolve as healing progresses:

• Nausea and vomiting – from conditioning chemotherapy
• Fatigue and weakness – common during the recovery period
• Mouth sores – managed with medications
• Low blood counts – temporary and monitored closely
• Febrile neutropenia – fever with low white blood cell count; managed as per department protocol
• Hair loss – temporary

Complication Rates

Transplant-related mortality (TRM) in the Indian multicentre study was 3.56%.

Other complications that may occur include:

• Infection – due to immunosuppression
• Bleeding – due to low platelet counts
• Graft failure – the stem cells fail to engraft
• Organ damage – from conditioning chemotherapy
• Secondary cancers – rare but possible

Top Indian hospitals follow international safety protocols, using advanced technology and rigorous pre-transplant screening to minimize risks and achieve optimal outcomes. Advanced transplant protocols minimize side effects and reduce risks.

5. Recovery and Aftercare

Recovery after aHSCT requires time and careful monitoring. The procedure involves several phases:

Stem Cell Collection and Storage

Mobilization is done with G-CSF, and a minimum of 2 × 10⁶ CD34 cells/kg is collected. The collected stem cells are then cryopreserved for later reinfusion.

Transplant Phase

Hospital stay: 3 to 6 weeks.
Engraftment: 2 to 4 weeks after transplant. The median time to neutrophil engraftment was 16.5 days, and platelet engraftment was 19 days in one study.
Mean time to discharge: 27.6 ± 8.3 days.
Return to normal activities: 6 to 12 months.
Typical stay in India for international patients: 6 to 12 weeks (including transplant, recovery, and initial follow-up).

Post-Treatment Care

After treatment, patients are advised to:

• Take prescribed medications as directed (including antibiotics, antifungals, and antivirals)
• Maintain strict hygiene to prevent infections
• Attend all scheduled follow-up appointments
• Monitor for signs of infection or complications
• Follow dietary guidelines provided by your medical team
• Avoid crowded places and people with infections

6. Cost of aHSCT in India

One of the most significant advantages of seeking aHSCT in India is the substantial cost savings—often 60-80% less than in Western countries—without compromising on quality.

Cost Comparison: India vs. Global

Detailed Cost Breakdown in India

aHSCT costs in India vary based on the condition, hospital, and type of procedure. Key estimates include:

• Autologous HCT cost: INR 699,200 (approximately $10,282) in a public sector study, where the hospital bore 34% of the cost.
• Stem cell therapy for MS: Typically ranges from $4,000 to $12,000 USD, with comprehensive AHSCT packages going up to $30,000 USD.Placidway
• Private hospital BMT: ₹10 lakh to ₹30 lakh per patient (approximately $12,000 – $36,000).Hindustan Times
• Bone marrow transplant average: ₹1,000,000 to ₹4,000,000 (approximately $12,000 – $48,000).Manipal Hospitals

In private hospitals, autologous transplants typically range from ₹10 lakh to ₹20 lakh (approximately $12,000 – $24,000).

Factors affecting the overall cost:

• Type of condition being treated
• Hospital location and reputation
• Length of hospital stay (3-6 weeks)
• Medications and supportive care required
• Additional treatments (e.g., rituximab for EBV reactivation)
• Pre- and post-transplant evaluations

What’s included in a typical package:

• Consultation with the hematologist
• Pre-transplant evaluation and diagnostic tests
• Stem cell mobilization and collection
• Stem cell cryopreservation
• Conditioning chemotherapy
• The transplant procedure
• Hospital stay (3-6 weeks)
• All medications during the stay
• Post-transplant follow-up consultations
• Dedicated patient coordinator assistance
• Airport pickup and drop-off

7. Top Hospitals for aHSCT

MedicHorizon partners with some of India’s most respected hospitals and stem cell transplant centers, all of which hold international accreditations and have a proven track record of successful aHSCT procedures.

Delhi NCR

• Fortis Memorial Research Institute, Gurugram – JCI and NABH accredited. FMRI has performed extensive stem cell transplant research and achieved outcomes among the best reported globally. A decade-long study on stem cell transplants for sickle cell disease demonstrated an overall survival rate of nearly 87%.Fortis Healthcare
• Rajiv Gandhi Cancer Institute & Research Centre, Delhi – A premier cancer hospital that has performed approximately 2,000 stem cell transplants since launching its program in 2007, including 200 transplants in a single year.RGCIRC
• Max Super Speciality Hospital, Saket, Delhi – Offers autologous BMT for autoimmune conditions, particularly multiple sclerosis, backed by high-dose and induction therapies, targeted treatments, immunotherapies, and advanced graft manipulation.Max Healthcare

Mumbai

• Fortis Hospital, Mulund, Mumbai – The Bone Marrow Department provides comprehensive care for patients of all age groups requiring bone marrow transplantation to treat a variety of blood disorders, including cancers. Access to modern equipment and best healthcare facilities for BMT patients across the globe.Fortis Healthcare
• Kokilaben Dhirubhai Ambani Hospital, Mumbai – JCI and NABH accredited. Offers comprehensive stem cell therapy and bone marrow transplant services with experienced specialists.

Hyderabad

• Yashoda Hospitals, Hitech City, Hyderabad – Launched a state-of-the-art Bone Marrow & Stem Cell Transplant Center, considered one of India’s largest and most advanced facilities. The center treats blood cancers such as leukemia, lymphoma, and multiple myeloma, as well as non-cancerous blood disorders.Yashoda Hospitals Dr. Ganesh Jaishetwar, Senior Hematologist and Bone Marrow Transplant Specialist, has performed over 300 bone marrow transplants at Yashoda Hospitals.Yashoda Hospitals

Bangalore

• Manipal Hospitals, Bangalore – NABH accredited. Manipal’s bone marrow transplant program has an average cost of ₹1,000,000 to ₹4,000,000 (approximately $12,000 – $48,000).Manipal Hospitals
• Ramaiah Memorial Hospital, Bangalore – Has been awarded FACT accreditation, becoming one of only two hospitals in India to hold this accreditation and the only one in the country to have both FACT and Joint Commission International (JCI) accreditations. FACT accreditation certifies compliance with internationally recognised FACT–JACIE standards, widely regarded as the gold standard in hematopoietic stem cell transplantation.Economic Times

Chennai

• Apollo Hospitals, Greams Road, Chennai – JCI accredited. Apollo is a pioneer in stem cell therapy and bone marrow transplantation in India, with a dedicated transplant program and successful outcomes.

Kolkata

• Apollo Hospitals Kolkata – NABH accredited. Offers comprehensive stem cell therapy and bone marrow transplant services.

These hospitals are equipped with state-of-the-art technology, employ experienced hematologists and transplant specialists, and have successfully treated thousands of international patients. All institutions in the MedicHorizon network hold international accreditations (NABH/JCI), ensuring you receive care that meets the highest global standards of safety and clinical excellence.

India has rapidly emerged as a global leader in stem cell therapy. With world-class infrastructure, expert specialists, and affordable treatment costs, India attracts thousands of patients from Africa, the Middle East, Europe, and Southeast Asia every year. Today, more than 100 centres offer HCT as standard therapy across India, with the Indian Society of Blood and Marrow Transplant having data of at least 3,200 transplants.

8. Frequently Asked Questions

Q1: What is the success rate of aHSCT in India?

Success rates vary by condition. For multiple myeloma, a multicentre study reported a 91% 1-year overall survival, 85% 2-year survival, and 72% 5-year survival, with 77% achieving complete remission at day +100. For pediatric patients, overall survival was 75% at a median follow-up of 33.2 months.

Q2: How much does aHSCT cost in India?

aHSCT in India costs between $3,000 and $30,000 USD (₹2.5 lakh to ₹30 lakh), depending on the condition and hospital.PlacidwayHindustan Times Autologous transplants typically range from ₹10 lakh to ₹20 lakh.

Q3: How long do I need to stay in India for aHSCT?

Plan for 6 to 12 weeks in India: 3-6 weeks for hospital stay and 3-6 weeks for initial recovery and follow-up before flying home.

Q4: Is aHSCT painful?

The procedure is performed under medical supervision with appropriate pain management. Some patients may experience discomfort during recovery, which is managed with prescribed medication.

Q5: What is the difference between autologous and allogeneic stem cell transplant?

Autologous (aHSCT) uses the patient’s own stem cells, eliminating the risk of graft-versus-host disease (GVHD). Allogeneic uses stem cells from a donor and carries a risk of GVHD but may offer a graft-versus-tumor effect.

Q6: What are the risks of aHSCT?

Common risks include infection, bleeding, graft failure, and organ damage. Transplant-related mortality in Indian studies is 3.56%. Serious complications are rare when performed by experienced specialists.

Q7: Can I travel alone for aHSCT?

It is strongly recommended to have a companion with you for support during your treatment and recovery. A caregiver is essential due to the longer hospital stay and recovery period.

Q8: Which hospitals in India are best for aHSCT?

Top hospitals include Fortis Memorial Research Institute (Gurugram), Rajiv Gandhi Cancer Institute (Delhi), Max Super Speciality Hospital (Delhi), Kokilaben Dhirubhai Ambani Hospital (Mumbai), Yashoda Hospitals (Hyderabad), Manipal Hospitals (Bangalore), and Apollo Hospitals (Chennai).

9. How MedicHorizon Assists with Your aHSCT Journey

Choosing aHSCT through MedicHorizon ensures seamless coordination and personalized support every step of the way.

We provide end-to-end facilitation beyond what a hospital’s international desk can offer:

1. Pre-Arrival Consultation: We review your medical history and help you select the right hospital and specialist for your needs. We can also facilitate video consultations with the doctor before you travel.
2. Medical Visa Assistance: We guide you through the e-Medical Visa process and provide hospital invitation letters required for your visa application.
3. Travel & Accommodation: We book affordable flights and comfortable accommodation near the hospital—from budget to 5-star options. Complimentary airport pickup and drop-off are included.
4. Hospital Admission & Daily Coordination: Our coordinator meets you on arrival, assists with hospital admission, and liaises with the medical team on your behalf so you can focus on your treatment and recovery.
5. Financial & Insurance Help: We explain payment options, provide transparent cost estimates, and coordinate with your insurer and the hospital’s TPA desk for cashless treatment where possible.
6. Post-Treatment Follow-Up: We arrange post-discharge consultations, assist with prescription refills and ongoing care coordination, and can book a stay at one of our recovery retreats for a relaxing conclusion to your medical journey.
7. Value-Added Services: Currency exchange, local SIM card, customised meal plans, prayer room access, and guidance on extending your stay to explore India.

For the latest research and clinical trial updates on aHSCT, visit our MedicHorizon Journal.

Ready to Explore aHSCT in India?

If you or a loved one is considering aHSCT, contact MedicHorizon today.

We’ll help you understand the process, connect with top hospitals and specialists, and plan your journey with transparency, compassion, and care.

📧 Email: contactmedichorizon@gmail.com
🌐 Website: MedicHorizon Treatments Directory

Legal Disclaimer

This article is for general informational and educational purposes only. MedicHorizon is a health hospitality consultancy, not a medical provider, hospital, or licensed medical practitioner. We do not diagnose, treat, prescribe, or offer medical opinions. All information regarding aHSCT is based on publicly available data and does not constitute medical advice. You should independently verify all information and consult with qualified healthcare professionals before making any treatment decisions. Any medical procedure carries inherent risks. By using our services, you acknowledge that all medical decisions remain solely your responsibility.